liensinine has been researched along with Dyslipidemias in 1 studies
*Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, R; Liang, L; Meng, S; Ye, S; Zhou, J; Zhou, X | 1 |
1 other study(ies) available for liensinine and Dyslipidemias
| Article | Year |
|---|---|
Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Cytokines; Diet, High-Fat; Dyslipidemias; Hepatocytes; Humans; Hypolipidemic Agents; Isoquinolines; Lipid Metabolism; Liver; Male; MAP Kinase Kinase Kinases; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Palmitic Acid; Phenols; Reactive Oxygen Species | 2022 |